February 3, 2011
Sunovion Drug Goes To Market
By Brandon Butler
Sunovion Pharmaceuticals Inc., which use to be Sepracor, announced that its schizophrenia treatment drug Latuda has begun selling in pharmacies across America.
The U.S. Food & Drug Administration approved Latuda in October, 2010 after four six-week placebo-controlled studies.
Saburo Hamanaka, chairman and CEO of the company, called the drug a "leading product for our company."
Sunovion also developed Lunesta, the insomnia treatment drug.
Sunovion is the U.S. subsidiary of Dianippon Sumitoro Pharmaceuticals, which is based in Japan. DSP purchased Marlborough-based Sepracor in September 2009. In July, the company dropped the Sepracor name and it is now referred to as Sunovion. Read about the company's transition here.
Read more
WBJ Web Partners
Most Recent
Most Recent
0 Comments